Genetics News

WATERTOWN, Mass. & STEVENAGE, England--(BUSINESS WIRE)--Dyno Therapeutics and Trisk Bio announce strategic manufacturing partnership through expanded Frontiers Program...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics unveils best-in-class Dyno-bn8 AAV vector for muscle gene therapies, achieving therapeutic delivery with improved safety potential...

LAGUNA HILLS, Calif. & HOUSTON--(BUSINESS WIRE)--Medley Therapeutics, Inc. (formerly YAP Therapeutics), a company developing regenerative genetic medicines and advanced biologics, today announced completion of dosing in the first cohort (n=3) of the Phase 1 SALVADOR-HF clinical trial evaluating YAP101 in patients with advanced ischemic heart failure with reduced ejection fraction (HFrEF) at The Texas Heart Institute at Baylor College of Medicine and at the St. Luke’s Medical Center (Houston). F...

DUBLIN--(BUSINESS WIRE)--Phase 2 clinical data for coramitug, a potential first-in-class amyloid depleter antibody, for the treatment of ATTR-CM published in Circulation....

OXFORD, England--(BUSINESS WIRE)--Evox Therapeutics announced the appointment of Douglas Treco, Ph.D., as a Non-Executive Director of the Company’s Board of Directors....

ALAMEDA, Calif.--(BUSINESS WIRE)--Santa Ana Bio, Inc., a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today announced the appointment of Mike Bonney as Chair of its Board of Directors. Jerel Davis, Ph.D., Managing Director at Versant Ventures and Santa Ana’s founding Chairman, will remain a director. “We’re very pleased to welcome industry veteran Mike to our board as Chair,” said Peter Emtage, Ph.D., founder and CEO of Santa...

CAMBRIDGE, England--(BUSINESS WIRE)--Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to end the morbidity and mortality of aging, today announced the release of new research detailing an improved framework for evaluating benchmark metric calibration in virtual cell models1. Using well-calibrated metrics, the study demonstrates that virtual cell models consistently outperform key baselines, providing valuable and actionable biological insights to acc...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to 5,407,500 shares of common stock at a combined price of $6.14 and, in lieu of common stock t...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The presentation includes data from the ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo g...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a conference call and webcast tomorrow, November 11, 2025, at 8:00 a.m. ET to discuss new preliminary data from its pivotal cohort in the ongoing LEGEND trial of its novel, non-viral gene therapy candidate, detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with high-ri...